title: Effect of anti-Helicobacter pylori therapy on outcome of iron-deficiency anemia: a randomized, controlled study.
abstract: BACKGROUND
  Helicobacter pylori infection may play a role in iron-deficiency anemia.
  
  
  METHODS
  In 52 patients with iron-deficiency anemia, H. pylori status was determined using rapid urease test and histology. H. pylori -positive patients were randomly assigned to receive anti- H. pylori treatment either immediately (Group I) or after a delay of one month (Group II); in addition, all patients received oral ferrous sulfate for three months. Patients testing negative for H. pylori (Group III) received only oral ferrous sulfate. Hematological parameters were tested every month.
  
  
  RESULTS
  Of 52 patients, 32 (61.5%) had H. pylori infection. At the end of one month, median increase in hemoglobin level was lower in Group II than in Groups I and III (1.1 g/dL vs. 3.6 g/dL and 1.9 g/dL, respectively; p=0.025), as were that in serum iron (19 mcg/dL vs. 55.5 mcg/dL and 41 mcg/dL; p=0.019). During the second month, after H. pylori infection in Group II had been treated, median increase in hemoglobin in this group was comparable to those in Groups I and III (3.7 g/dL vs. 2.5 g/dL and 2.5 g/dL.
  
  
  CONCLUSIONS
  In patients with iron-deficiency anemia, presence of H. pylori infection is associated with a poorer response to oral iron therapy, which improves with treatment for H. pylori infection.
authors.affiliation: Department of Medicine, Jawaharlal Nehru Institute of Postgraduate Medical Education and Research, Pondicherry, India.
authors.forename: Asha N
authors.initials: AN
authors.lastname: Valiyaveettil
authors.forename: Abdoul
authors.initials: A
authors.lastname: Hamide
authors.forename: Zachariah
authors.initials: Z
authors.lastname: Bobby
authors.forename: R
authors.initials: R
authors.lastname: Krishnan
mesh_terms: D018798:Anemia, Iron-Deficiency / Q000188:drug therapy / Q000453:epidemiology*; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D005296:Ferrous Compounds / Q000008:administration & dosage; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000453:epidemiology*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D003692:Delayed-Action Preparations; D005296:Ferrous Compounds; C020748:ferrous sulfate